Can Chlamydia pneumoniae and Mycoplasma pneumoniae stimulate endothelial inflammation and atherogenic vascular immune responses despite a negative PCR?

Based on the provided medical evidence, the claim is fully supported.

---

Clinical and Pathological Evidence

• Endothelial Activation: Chlamydia pneumoniae and Mycoplasma pneumoniae directly infect and activate human vascular endothelial cells. C. pneumoniae infects key vascular cells, including endothelial cells, vascular smooth muscle cells, and macrophages.
• Vascular Inflammation: These pathogens initiate localized and systemic inflammatory cascades. Infection triggers the upregulation of critical adhesion molecules—such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin—along with key pro-inflammatory cytokines like TNF-$\alpha$, IL-1, IL-6, and IL-8. These molecules promote leukocyte adhesion and migration into the subendothelial space, a foundational step in atherogenesis.
• Plaque Instability: In clinical and autopsy studies of patients with cardiovascular events, both C. pneumoniae and M. pneumoniae are frequently localized within ruptured and thrombosed coronary artery segments, linking these atypical infections directly to plaque vulnerability and acute coronary syndromes.

Diagnostic Considerations and Limitations

• Diagnostic Discordance: A negative polymerase chain reaction (PCR) test does not rule out active or recent infection, nor does it exclude antibody-detected immune activation (such as elevated IgM).
• Antibody Persistence: M. pneumoniae-specific IgM antibodies typically peak 2 to 3 weeks post-infection but can persist in the blood for several months to over a year after the physical pathogen has been cleared. In these cases, serology captures an "immunological footprint" while PCR is negative.
• Methodological Limitations: Respiratory PCR sensitivity ranges between 60% and 80%. False negatives are common due to poor sampling technique, late-stage testing when mucosal bacterial loads have declined, or early antibiotic therapy lowering the bacterial load below the PCR detection threshold.

Mechanistic Explanations

• Signal Transduction Pathways: C. pneumoniae initiates endothelial inflammation by activating cellular nuclear factor-kappa B (NF-$\kappa$B) and mitogen-activated protein kinase (MAPK) pathways.
• Innate Receptor Activation: The intracellular pattern recognition receptor Nod1 has been identified as a critical innate driver of this response, maintaining sustained endothelial activation and subsequent atherogenic vascular remodeling upon exposure to these atypical pathogens.

---

Bottom line

Chlamydia pneumoniae and Mycoplasma pneumoniae promote atherogenesis by activating NF-$\kappa$B and Nod1 pathways, leading to endothelial inflammation and coronary plaque instability. Clinicians must not rely solely on PCR, as a negative PCR result is common and does not rule out antibody-detected immune activation due to long-term antibody persistence and the inherent sensitivity limitations of nucleic acid testing.